Autophagy Inhibition Reprograms the Tumor Microenvironment of Pancreatic Cancer to Promote Macrophage Phagocytosis of Tumor Cells.

Autophagy inhibition in pancreatic ductal adenocarcinoma (PDAC) enhances macrophage recruitment and tumor cell phagocytosis, with significant effects observed through the CXCL1/2-CXCR2 axis.

• Why it matters: Understanding how to manipulate the tumor microenvironment (TME) to promote immune-mediated tumor destruction is critical for improving PDAC treatment, as current therapies are limited.
• What they did: The study used autophagy inhibition in PDAC models, revealing that it decreases CD47 on tumor cells and recruits macrophages via the CXCL1/2-CXCR2 pathway, with CD8+ T cells supporting macrophage activity.
• The result: Findings demonstrate that autophagy inhibition reprograms the TME to stimulate macrophage phagocytosis, offering a promising strategy to enhance immune responses and improve outcomes in pancreatic cancer.